A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease
Launched by UNIVERSITY OF SYDNEY · Nov 2, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The REBUILD-SM Study is looking to see if a special smartphone app called REBUILD-SM can help people with interstitial lung disease (ILD) live better lives compared to standard care. The main goal is to find out if using this app can improve patients' quality of life, reduce symptoms, lower anxiety, boost confidence in managing their health, and increase physical activity. Participants in the study will be divided into two groups: one will use the full app with support from a healthcare professional, while the other will use a simpler version of the app.
To join the study, participants need to be diagnosed with fibrotic ILD, own a smartphone or tablet, and be able to read and understand English. They should also have been on stable treatment for ILD for at least 30 days. Throughout the trial, participants will track their health progress using the app. This study is currently recruiting individuals aged 65 to 74, and it’s a chance to contribute to research that could help improve care for others with similar lung conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of fibrotic ILD
- • In possession of a smartphone/tablet and an email address
- • Able to understand written and spoken English
- • Adequate digital literacy to complete requirements of trial
- • On stable ILD treatment for 30 days prior to enrolment
- Exclusion Criteria:
- • Not in possession of a smartphone/tablet
- • Insufficient digital literacy to complete requirements of trial
- • Unable to communicate in written/spoken English
- • Not on stable ILD treatment for 30 days prior to enrolment
- • Acute exacerbation within 30 days prior to enrolment
- • Participating in pulmonary rehab at enrolment or during 12-week intervention period
- • Unable to provide informed consent
About University Of Sydney
The University of Sydney is a leading research institution in Australia, renowned for its commitment to advancing medical science and improving healthcare outcomes through innovative clinical trials. With a robust infrastructure and a multidisciplinary team of experts, the university fosters a collaborative environment that integrates cutting-edge research with clinical practice. The institution emphasizes ethical standards, patient safety, and scientific rigor in its trials, aiming to translate findings into real-world applications that benefit diverse populations. Through its dedication to excellence and impact, the University of Sydney continues to contribute significantly to the fields of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Melbourne, Victoria, Australia
Sydney, New South Wales, Australia
Melbourne, Victoria, Australia
Brisbane, Queensland, Australia
Patients applied
Trial Officials
Tamera Corte
Principal Investigator
University of Sydney
Dan Chambers
Principal Investigator
The University of Queensland
Nicole Goh
Principal Investigator
Institute of Breathing and Sleep
Ian Glaspole
Principal Investigator
The Alfred
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported